Ensysce Biosciences Inc (ENSC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $7.97M
Last updated: Nov 17, 2026 at 4:10 PM ET
Ensysce Biosciences Inc (ENSC) Statistics
Ensysce Biosciences (ENSC) has a market cap of $7.97M. Its share count is up 530.38% from a year earlier. It holds $29.52M more cash than debt, 370.45% of its market cap.
Total Valuation
| Market Cap | $7.97M |
|---|---|
| Latest price (Nov 17, 2026) | $0.38 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 1.1x and 0.3x.
| P/S Ratio | 1.1x |
|---|---|
| Forward P/S | 1.7x |
| P/B Ratio | 0.3x |
Price Statistics
The stock is down 81.37% over 52 weeks and trades 13.64% below its 50-day average.
| Beta (1Y) | 1.33 |
|---|---|
| 52-Week Change | -81.37% |
| 1-Month Change | -23.68% |
| 3-Month Change | -1.08% |
| 6-Month Change | +29.53% |
| 5-Year Change | -99.99% |
| Total Return (1Y) | -81.37% |
| Total Return (3Y CAGR) | -69.53% |
| Total Return (5Y CAGR) | -85.51% |
| Max Drawdown (1Y) | -87.19% |
| Max Drawdown (3Y) | -98.97% |
| Sharpe Ratio (1Y) | -1.27 |
| Correlation with SPY (1Y) | 0.14 |
| 50-Day Average | $0.44 |
| 200-Day Average | $0.40 |
| 52-Week Range | $0.23 to $1.95 |
| RSI (14 Days) | 43.6 |
| Average Volume (20 Days) | 290.53K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 8.02x current liabilities, and total debt is 0.01x shareholder equity.
| Current Ratio | 8.02x |
|---|---|
| Quick Ratio | 8.02x |
| Debt / Equity | 0.01x |
| Interest Coverage | -899.84x |
Returns and Efficiency
Return on invested capital is -32.90% over the last 12 months.
| Return on Assets (ROA) | -294.02% |
|---|---|
| Return on Invested Capital (ROIC) | -32.90% |
| Receivables Turnover | 26.85x |
| Cash Conversion Cycle | -98 days |
Scores
ENSC has an Altman Z-Score of -9.20, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -9.20 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Balance Sheet
| Cash and Equivalents | $29.67M |
|---|---|
| Total Debt | $154.87K |
| Net Cash | $29.52M |
| Net Cash Per Share | $1.62 |
Balance sheet as of Sep 30, 2026.
Growth
Revenue grew 26.16% a year over 3 years.
| Revenue Growth (3Y CAGR) | +26.16% |
|---|---|
| Revenue Growth (5Y CAGR) | +5.21% |
Stock Splits
The last split was a 1-for-15 reverse split on Dec 6, 2024.
| Last Split Date | Dec 6, 2024 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:15 |
Analyst Forecast
Consensus estimates put revenue growth at -19.56% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -19.56% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About ENSC
What is ENSC's market cap?
Ensysce Biosciences has a market cap of $7.97M.
How many shares of ENSC are outstanding?
Ensysce Biosciences has 18.19M shares outstanding. The count is up 530.38% from a year earlier.
Does ENSC pay a dividend?
No. Ensysce Biosciences does not pay a dividend.
How much debt does ENSC have?
Ensysce Biosciences has $154.87K of total debt and $29.67M of cash and equivalents, a net cash position of $29.52M.
ENSC pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors